Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model. 2007

Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
Goldschleger Eye Institute, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel. barequet@cs.technion.ac.il

OBJECTIVE To compare the rate of epithelial healing of corneal erosion in an animal model with 2 commercial formulations of fourth-generation fluoroquinolones: 0.3% gatifloxacin and 0.5% moxifloxacin. METHODS Corneal erosions, 6 mm in diameter, were created in 28 rabbit eyes. The rabbits were randomized to receive topical gatifloxacin, moxifloxacin, or nonpreserved saline. Drops were administered every 15 minutes for 1 hour, then hourly for 3 hours, and then 4 times daily until the erosion reepithelialized. Eyes were examined with fluorescein drops and photographed every 12 hours with a cobalt blue-filtered light. When reepithelialization was observed, the rabbits were euthanized, and their eyes were enucleated for histopathologic evaluation. RESULTS Reepithelialization of the corneal erosions was fastest in the saline-treated eyes (57.3 +/- 8 hours), followed by moxifloxacin (62.7 +/- 11.7 hours) and gatifloxacin (66 +/- 8.5 hours). These differences in the time to closure of the erosions among the 3 groups were not statistically significant. Although significant differences were found among the healing progression curves when all 3 groups were compared (P = 0.042), the difference between the 2 antibiotic-treated groups was not significant. CONCLUSIONS Only slight differences in epithelial healing rates were found between the gatifloxacin-, moxifloxacin-, and saline-treated groups, suggesting that the 2 fluoroquinolones may have an equivalent role as prophylactic treatment of trauma- or surgery-induced corneal erosions.

UI MeSH Term Description Entries
D008297 Male Males
D011804 Quinolines
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D003316 Corneal Diseases Diseases of the cornea. Corneal Disease,Disease, Corneal,Diseases, Corneal
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000077266 Moxifloxacin A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent. 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid,Actira,Avalox,Avelox,BAY 12-8039,BAY 128039,BAY-12-8039,BAY-128039,Izilox,Moxifloxacin Hydrochloride,Octegra,Proflox,BAY 12 8039,BAY128039
D000077734 Gatifloxacin A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS. 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid,AM 1155,AM-1155,BMS-206584,CG 5501,Gatifloxacine,Tequin,Zymar,BMS 206584,BMS206584
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001372 Aza Compounds Organic chemicals where carbon atoms have been replaced by nitrogen atoms. Compounds, Aza

Related Publications

Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
October 2006, Cornea,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
October 2005, Cornea,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
October 2014, Cornea,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
December 2016, Cornea,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
July 2005, American journal of ophthalmology,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
October 2008, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
November 2010, Cornea,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
April 2009, Lancet (London, England),
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
April 2009, Advances in therapy,
Irina S Barequet, and Zohar Habot-Wilner, and Fabio Lavinsky, and Hana Ziv, and Michael Belkin, and Mordechai Rosner
October 2001, Revue medicale de Bruxelles,
Copied contents to your clipboard!